. Financial highlights Direct sales of MagnetOs rose 75% from CHF 6.9 million to CHF 12.1 million in 2022. Total revenue from medical devices CHF 13.3 million, up from CHF 8.3 million Revenue from collaboration CHF 4.7 million vs CHF 5.5 million in 2021, due to licensing agreement with Checkmate Pharmaceuticals Cash & cash equivalents, […]
Read MoreAutor: Firma Kuros Biosciences
Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
Publications in peer reviewed Journal of Immunology and Regenerative Medicine and Clinical Oral Implants Research Adds to body of evidence for MagnetOs, using data from human and animal models Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announced the publication of key scientific data on the efficacy of […]
Read MoreKuros Biosciences Announces Changes to Executive Management Team
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad interim, effective February 17, 2023. Daniel Geiger succeeds Michael Grau, who will handover his CFO position. Joost de Brujin, Chief Executive Officer of Kuros, said: "We are honoured […]
Read MoreKuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
. First investigational trial of drug-biologic bone graft for spinal fusion No drug-related Serious Adverse Events (SAEs) reported in randomized stage of the trial Enrollment of additional 20 patients for second non-randomized stage underway Potential to address a major commercial opportunity Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, […]
Read MoreKuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
Preliminary data shows 78% fusion rate vs 42% for autograft and 55-71% for other synthetic bone grafts Level 1 clinical study compares MagnetOs Granules to local autograft in patients undergoing posterolateral lumbar fusion First of five randomized controlled Level 1 trials for MagnetOs to complete enrolment Kuros Biosciences (“Kuros” or the “Company”), a leader in […]
Read MoreKuros reports 73% increase in MagnetOs sales in first nine months of 2022
Total product sales grow to CHF 8.9 million in the first nine months of 2022 Reaches major milestone of 10,000 patients treated with MagnetOs Positive first clinical data from planned randomized controlled trials Full commercial launch of MagnetOs Flex Matrix that recently received the Spine Technology Award from Orthopedics This Week With recent PIPE cash […]
Read MoreKuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
. MagnetOs Flex Matrix recognized as exemplary and innovative spine surgery product Rounds out MagnetOs portfolio to provide more solutions for surgeons Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, today announces that it has received the 2022 Spine Technology Award from the widely-read industry publication Orthopedics This […]
Read MoreKuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
First clinical data from five planned randomized controlled trials Show favorable fusion rate compared to autograft Launch of MagnetOs Flex Matrix expands perioperative options for surgeons Schlieren (Zurich), Switzerland, 11 October, 2022 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will present compelling clinical […]
Read MoreKuros Biosciences Appoints Chris Fair as Chief Operating Officer
Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it has appointed Chris Fair as Chief Operating Officer (COO). Mr. Fair is a leader in the musculoskeletal and regenerative medicine industry with more than 25 years of experience in overseeing and guiding organizations through development, growth and […]
Read MoreKuros Biosciences announces successful CHF 6.0 million private placement
Kuros Biosciences AG (SIX:KURN) a leader in next generation bone graft technologies, announced today the successful completion of a CHF 6.0 million capital increase through a private placement of 3,750,000 new shares of Kuros with a par value of CHF 0.10 each (the "New Shares" and the "Placement", respectively). The New Shares have been placed […]
Read More